General Hospital Of Larissa Koutlibaneio And Triantafylleio
- Address
- lock Available on a paid plan
Therapeutics
The department is evaluating innovative drug candidates to improve outcomes for patients with sickle cell disease and transfusion‑dependent thalassemia, as well as therapies for severe hospital‑acquired pneumonia.
- Novel oral activators targeting hemoglobin function
- Combination regimens for hydroxyurea‑non‑eligible patients
- Dose‑finding studies in myelodysplastic syndrome cohorts
Research conducted at General Hospital Of Larissa Koutlibaneio And Triantafylleio showcases a commitment to advancing therapeutic options for hematologic disorders.
Bacterial Infections and Mycoses
Trials aim to reduce mortality from hospital‑acquired pneumonia and sepsis through early, biomarker‑guided antibiotic strategies.
- PSP‑guided early meropenem administration
- Dexamethasone added to standard care for inflammatory pneumonia
- Evaluation of pro‑inflammatory phenotypes as trial endpoints
The site’s focus on rapid infection management reflects its expertise in acute care within the Larissa region.
Eye Diseases
A non‑inferiority study compares a preservative‑free Brimonidine/Timolol eye‑drop formulation with the standard product for patients with open‑angle glaucoma.
- Intra‑ocular pressure reduction at 08:00
- Safety and tolerability of preservative‑free solution
- Patient‑reported comfort and adherence
The department’s ophthalmic research complements its hematology program, offering comprehensive care at the hospital.
Hemic and Lymphatic Diseases
Clinical investigations target the underlying mechanisms of hemoglobinopathies and related marrow disorders, seeking to lessen transfusion burden.
- Long‑term safety of etavopivat across sickle cell and thalassemia populations
- Dose‑response evaluation of SP‑420 in transfusion‑dependent patients
- Assessment of quality‑of‑life improvements
General Hospital Of Larissa’s hematology unit leverages multidisciplinary expertise to address complex blood diseases.
Pathological Conditions, Signs and Symptoms
Research also addresses clinical signs such as elevated intra‑ocular pressure and systemic inflammatory markers to refine diagnostic and monitoring tools.
- Monitoring IOP changes in glaucoma therapy trials
- Use of qSOFA and NEWS2 scores for early sepsis detection
- Correlation of PSP levels with infection risk
These studies highlight the site’s dedication to integrating diagnostic precision with therapeutic innovation.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 6 therapeutic areas and 11 of 12 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 6 by active trials.
- 1Novo Nordisk A/S1active
lock +5 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novo Nordisk A/S3trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 173 other sites in Greece
Therapeutic Area Benchmark — Greece
Select a therapeutic area to compare against other sites in Greece.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Greece
Market Share
Country: Greece
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in General Hospital Of Larissa Koutlibaneio And Triantafylleio
lock Showing 1 of 9 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2 Study for the Treatment of Anemia with Alpha (α)-Thalassemia to Determine the Efficacy and Safety of Luspatercept (BMS-986346/ACE-536) in Adults and Evaluate the Safety and Pharmacokinetics in Adolescents | Celgene Corp. | Phase II | Recruiting | Jan 2023 | — |
IMP list
lock Showing 1 of 12 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Etavopivat | 2 | Unknown | 2021-12-16 | 2025-01-09 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.